| || |
|Page 1 of 1 || Previous | Next |
| || | DIABETES IN CONTROL
JULY 20, 2015 [Mononeuropathy] Editor's Note, DCMS #250
The drug reps for DPP-4 inhibitors, GLP-1 agonists, and various insulins have been having a field day talking to prescribers about the possible cardiovascular effects of SGLT-2 inhibitors. This along with the relatively small risk of UTI's has possibly caused some of our readers to shy away from the whole class.